



QA0237 DIV 1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rosemary M. Miano

Type or print name

September 14, 2007

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF KATERINA LEFTHERIS, ET AL
FOR: NP TITLE - METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND
PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
DIV TITLE - METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND
PYRROLOTRIAZINE COMPOUNDS

APPLICATION NO: 10/696,178

ART UNIT: 1616

CONFIRMATION NO: 6531

APPLICATION DATE: 10/29/2003

EXAMINER: PRYOR, ALTON NATHANIEL

USPTO CUSTOMER NO: 23914

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

References 1A and 1C were cited in a supplementary European Search Report. Copies of these references and the search report are enclosed herewith. References 1B and 1D through 1K were cited previously in this action, on November 22, 2004. However, due to applicant's listing of volumes and pages, but omitting titles, Examiner did not review and initial citations. As such, references are being resubmitted at this time.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by initialing each reference in the spaces provided, and returning a copy of the initialed PTO 1449 form(s). Applicant believes that there is no fee

required with this filing of this paper. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

Statement under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby state that each new item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Statement under 37 C.F.R. §1.704(d)

I, the undersigned attorney, hereby state that each new item of information contained in this information disclosure statement was cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Date: September 14, 2007

Roseman Miano
Attorney for Applicant

Reg. No. 29,674

Phone: 609-252-6885